|
|
| (3 intermediate revisions not shown.) |
| Line 1: |
Line 1: |
| | | | |
| | ==NMR solution structures of the vMIP-II 1-10 peptide from Kaposi's sarcoma-associated herpesvirus.== | | ==NMR solution structures of the vMIP-II 1-10 peptide from Kaposi's sarcoma-associated herpesvirus.== |
| - | <StructureSection load='1hff' size='340' side='right' caption='[[1hff]], [[NMR_Ensembles_of_Models | 55 NMR models]]' scene=''> | + | <StructureSection load='1hff' size='340' side='right'caption='[[1hff]]' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[1hff]] is a 1 chain structure. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1HFF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1HFF FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[1hff]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Human_gammaherpesvirus_8 Human gammaherpesvirus 8]. Full experimental information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1HFF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1HFF FirstGlance]. <br> |
| - | </td></tr><tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1hfg|1hfg]], [[1cm9|1cm9]], [[1vmp|1vmp]]</td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Solution NMR</td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1hff FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1hff OCA], [http://pdbe.org/1hff PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=1hff RCSB], [http://www.ebi.ac.uk/pdbsum/1hff PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=1hff ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1hff FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1hff OCA], [https://pdbe.org/1hff PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=1hff RCSB], [https://www.ebi.ac.uk/pdbsum/1hff PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1hff ProSAT]</span></td></tr> |
| | </table> | | </table> |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/VMI2_HHV8P VMI2_HHV8P]] Blocks infection by several different human immunodeficiency virus type 1 (HIV-1) strains. This occurs because vMIP-II binds to a wide range of chemokine receptors. May form part of the response to host defenses contributing to virus-induced neoplasia and may have relevance to KSHV and HIV-I interactions. | + | [https://www.uniprot.org/uniprot/VMI2_HHV8P VMI2_HHV8P] Blocks infection by several different human immunodeficiency virus type 1 (HIV-1) strains. This occurs because vMIP-II binds to a wide range of chemokine receptors. May form part of the response to host defenses contributing to virus-induced neoplasia and may have relevance to KSHV and HIV-I interactions. |
| | <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| | == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
| Line 22: |
Line 22: |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Clark-Lewis, I]] | + | [[Category: Human gammaherpesvirus 8]] |
| - | [[Category: Crump, M P]] | + | [[Category: Large Structures]] |
| - | [[Category: Elisseeva, E]] | + | [[Category: Clark-Lewis I]] |
| - | [[Category: Gong, J H]] | + | [[Category: Crump MP]] |
| - | [[Category: Sykes, B D]] | + | [[Category: Elisseeva E]] |
| - | [[Category: Anatagonist]] | + | [[Category: Gong JH]] |
| - | [[Category: Chemokine]] | + | [[Category: Sykes BD]] |
| - | [[Category: Cxcr4]]
| + | |
| - | [[Category: Vmip-ii]]
| + | |
| Structural highlights
Function
VMI2_HHV8P Blocks infection by several different human immunodeficiency virus type 1 (HIV-1) strains. This occurs because vMIP-II binds to a wide range of chemokine receptors. May form part of the response to host defenses contributing to virus-induced neoplasia and may have relevance to KSHV and HIV-I interactions.
Publication Abstract from PubMed
Kaposi's sarcoma-associated herpesvirus encodes a chemokine called vMIP-II that has been shown to be a broad range human chemokine receptor antagonist. Two N-terminal peptides, vMIP-II(1-10) and vMIP-II(1-11)dimer (dimerised through Cys11) were synthesised. Both peptides are shown to bind the CXC chemokine receptor 4 (CXCR4). vMIP-II(1-10) was 1400-fold less potent than the native protein whilst the vMIP-II(1-11)dimer was only 180-fold less potent. In addition, both peptides are CXCR4 antagonists. Through analysis of non-standard, long mixing time two-dimensional nuclear Overhauser enhancement spectroscopy experiments, 13C relaxation data and amide chemical shift temperature gradients for the N-terminus of vMIP-II, we show that this region populates a turn-like structure over residues 5-8, both in the presence and absence of the full protein scaffold. This major conformation is likely to be in fast exchange with other conformational states but it has not previously been detected in monomeric chemokine structures. This and other studies [Elisseeva et al. (2000) J. Biol. Chem. 275, 26799-26805] suggest that there may be a link between the structuring of the short N-terminal chemokine peptides and their ability to bind their receptor.
Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10).,Crump MP, Elisseeva E, Gong J, Clark-Lewis I, Sykes BD FEBS Lett. 2001 Feb 2;489(2-3):171-5. PMID:11165244[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Crump MP, Elisseeva E, Gong J, Clark-Lewis I, Sykes BD. Structure/function of human herpesvirus-8 MIP-II (1-71) and the antagonist N-terminal segment (1-10). FEBS Lett. 2001 Feb 2;489(2-3):171-5. PMID:11165244
|
